Andrew Saik Intercept Pharmaceuticals, Inc. (ICPT) insider trading activity

Andrew Saik is EVP & Chief Financial Officer of INTERCEPT PHARMACEUTICALS, INC.. Currently has a direct ownership of 0 shares of ICPT, which is worth approximately $0. The most recent transaction as insider was on Nov 08, 2023, when has been sold 45,244 shares (Common Stock) at a price of $19.0 per share, resulting in proceeds of $859,636. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Andrew Saik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 08 2023	SELL Sale (or disposition) back to the issuer	$859,636 $19.0 p/Share	45,244 Reduced 100.0%	0 Common Stock
Nov 08 2023	SELL Disposition due to a tender of shares in a change of control transaction	$437,399 $19.0 p/Share	23,021 Reduced 100.0%	0 Common Stock
Sep 21 2023	SELL Payment of exercise price or tax liability	$9,806 $10.8 p/Share	908 Reduced 1.31%	68,265 Common Stock
Jun 21 2023	SELL Payment of exercise price or tax liability	$10,659 $11.74 p/Share	908 Reduced 1.3%	69,173 Common Stock
Mar 21 2023	SELL Payment of exercise price or tax liability	$12,898 $14.19 p/Share	909 Reduced 1.28%	70,081 Common Stock
Jan 27 2023	BUY Grant, award, or other acquisition	-	14,700 Added 17.15%	70,990 Common Stock
Dec 31 2022	SELL Payment of exercise price or tax liability	$8,881 $12.37 p/Share	718 Reduced 1.26%	56,290 Common Stock
Dec 21 2022	SELL Payment of exercise price or tax liability	$12,194 $13.43 p/Share	908 Reduced 1.57%	57,008 Common Stock
Sep 21 2022	SELL Payment of exercise price or tax liability	$13,484 $14.85 p/Share	908 Reduced 1.54%	57,916 Common Stock
Jun 21 2022	SELL Payment of exercise price or tax liability	$45,327 $12.48 p/Share	3,632 Reduced 5.82%	58,824 Common Stock
Jan 27 2022	BUY Grant, award, or other acquisition	-	10,300 Added 14.16%	62,456 Common Stock
Jun 21 2021	BUY Grant, award, or other acquisition	-	52,156 Added 50.0%	52,156 Common Stock

Also insider at

VYNE

VYNE Therapeutics Inc. Healthcare

Chief Financial Officer

ARVN

ARVINAS, INC. Healthcare

Chief Financial Officer

MIST

Milestone Pharmaceuticals Inc. Healthcare

Andrew Saik

EVP & Chief Financial Officer

Morristown, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ICPT shares.

Notify only if

Value

Insider Trading

Get notified when an Intercept Pharmaceuticals, Inc. insider buys or sells ICPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to INTERCEPT PHARMACEUTICALS, INC.

Account